var data={"title":"Contrast-enhanced ultrasound: Gastrointestinal applications outside of the liver","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Contrast-enhanced ultrasound: Gastrointestinal applications outside of the liver</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/contributors\" class=\"contributor contributor_credentials\">Christoph F Dietrich, MD, MBA</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/contributors\" class=\"contributor contributor_credentials\">Jonathan B Kruskal, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/contributors\" class=\"contributor contributor_credentials\">Kristen M Robson, MD, MBA, FACG</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Dec 12, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H20842311\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Contrast-enhanced ultrasound (CEUS) is a well-established technique for imaging the liver and other organs [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/1-6\" class=\"abstract_t\">1-6</a>]. It is used in most of Europe and Asia, as well as in many other countries worldwide, and guidelines are available [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/7,8\" class=\"abstract_t\">7,8</a>]. The contrast agent used for CEUS of the liver has been approved by the US Food and Drug Administration [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/9\" class=\"abstract_t\">9</a>]; however, its use in the United States has been mainly limited to research settings [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/1,2,10\" class=\"abstract_t\">1,2,10</a>]. CEUS is most often used for imaging the liver, but it has also been used to image other gastrointestinal organs, as well as non-gastrointestinal organs such as the heart, spleen, kidneys, and breast [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/5\" class=\"abstract_t\">5</a>]. (See <a href=\"topic.htm?path=contrast-echocardiography-clinical-applications\" class=\"medical medical_review\">&quot;Contrast echocardiography: Clinical applications&quot;</a> and <a href=\"topic.htm?path=contrast-echocardiography-contrast-agents-safety-and-imaging-technique\" class=\"medical medical_review\">&quot;Contrast echocardiography: Contrast agents, safety, and imaging technique&quot;</a>.)</p><p>This topic will review the use of CEUS in the pancreas, hepatobiliary system, and gastrointestinal tract. The use of CEUS for the evaluation of liver lesions is discussed separately. (See <a href=\"topic.htm?path=contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions\" class=\"medical medical_review\">&quot;Contrast-enhanced ultrasound for the evaluation of liver lesions&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H20842317\"><span class=\"h1\">GENERAL PRINCIPLES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Contrast-enhanced ultrasound (CEUS) uses ultrasound contrast agents to improve visualization and characterization of anatomic structures and lesions. Ultrasound contrast agents are 1 to 10 microns in size (equal to or smaller than red blood cells) and permit visualization of both the larger blood vessels and the microvasculature. CEUS permits real-time visualization of contrast-enhancement patterns during the arterial and venous phases, and in the case of the liver, the portal-venous phase [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/11\" class=\"abstract_t\">11</a>]. The general principles behind CEUS, as well as advantages of CEUS over conventional B-mode ultrasonography, computed tomography, and magnetic resonance imaging, are discussed in detail elsewhere. (See <a href=\"topic.htm?path=contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions#H92235607\" class=\"medical medical_review\">&quot;Contrast-enhanced ultrasound for the evaluation of liver lesions&quot;, section on 'General principles'</a> and <a href=\"topic.htm?path=contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions#H60340511\" class=\"medical medical_review\">&quot;Contrast-enhanced ultrasound for the evaluation of liver lesions&quot;, section on 'Advantages of CEUS'</a>.)</p><p class=\"headingAnchor\" id=\"H63411422\"><span class=\"h1\">TECHNICAL ASPECTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Contrast-enhanced ultrasound (CEUS) can be performed using a traditional transcutaneous approach or in combination with endoscopic ultrasound (typically done for the evaluation of pancreatic lesions). Only small amounts of ultrasound contrast agents are required for CEUS. For non-liver indications, a dose of 2.4 mL is often sufficient.</p><p class=\"headingAnchor\" id=\"H63411985\"><span class=\"h2\">Transcutaneous contrast-enhanced ultrasound</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Prior to performing CEUS, a conventional transcutaneous (B-mode) ultrasound examination is performed. The ultrasound contrast agent is then injected and imaging is obtained from the arterial and venous phases. The arterial phase is marked by the first visualization of the contrast agent (typically 10 to 20 seconds after contrast injection). Enhancement increases progressively through the arterial phase. The venous phase starts approximately 30 to 45 seconds after contrast injection and is marked by plateauing of the enhancement followed by a progressive decrease in enhancement until the microbubbles are no longer seen. Different enhancement patterns can help identify a lesion&rsquo;s vascular composition, which can assist with lesion identification.</p><p class=\"headingAnchor\" id=\"H63411624\"><span class=\"h2\">Contrast-enhanced endoscopic ultrasound</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Endoscopic ultrasound (EUS) overcomes some of the disadvantages of transcutaneous ultrasound techniques, including limited visualization of the pancreas in many patients. As with transcutaneous CEUS, the addition of a contrast agent when performing EUS (CE-EUS) can help delineate and identify lesions based on their pattern of vascular enhancement. (See <a href=\"topic.htm?path=endoscopic-ultrasound-normal-pancreaticobiliary-anatomy\" class=\"medical medical_review\">&quot;Endoscopic ultrasound: Normal pancreaticobiliary anatomy&quot;</a> and <a href=\"topic.htm?path=endoscopic-ultrasound-in-chronic-pancreatitis\" class=\"medical medical_review\">&quot;Endoscopic ultrasound in chronic pancreatitis&quot;</a> and <a href=\"topic.htm?path=endoscopic-ultrasound-in-the-staging-of-exocrine-pancreatic-cancer\" class=\"medical medical_review\">&quot;Endoscopic ultrasound in the staging of exocrine pancreatic cancer&quot;</a>.)</p><p>Two different techniques are used for CE-EUS [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/5\" class=\"abstract_t\">5</a>]. The first is contrast-enhanced high-mechanical index (MI) EUS (CEHMI-EUS). In CEHMI-EUS, ultrasound contrast agents are used to enhance Doppler signals [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/12,13\" class=\"abstract_t\">12,13</a>]. The advantages of this technique are that it does not require contrast-specific software and that it only adds an additional three to four minutes to the standard EUS examination [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/14\" class=\"abstract_t\">14</a>]. However, Doppler ultrasonography is limited by artifacts, poor spatial resolution, and low sensitivity to low flow [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/15\" class=\"abstract_t\">15</a>]. </p><p>The other technique, contrast-enhanced low-MI EUS, does require contrast-specific software, but it provides a detailed, high-resolution examination of the vascular architecture of parenchymal tissue to help characterize a lesion [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/16\" class=\"abstract_t\">16</a>]. </p><p class=\"headingAnchor\" id=\"H12520289\"><span class=\"h2\">Contrast agent dosing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The dose of the ultrasound contrast for non-liver indications is typically 2.4 mL [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/5,17\" class=\"abstract_t\">5,17</a>]. The dose may be adjusted based on the sensitivity of the equipment being used, the type of transducer, and the organ under investigation. The dose can be increased to 4.8 mL when using higher frequency transducers, including those used for CE-EUS. </p><p class=\"headingAnchor\" id=\"H20842323\"><span class=\"h1\">PANCREAS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Contrast-enhanced ultrasound (CEUS) techniques (transcutaneous CEUS and contrast-enhanced endoscopic ultrasound [CE-EUS]) can be used for evaluating pancreatic neoplasia and inflammatory lesions [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/5\" class=\"abstract_t\">5</a>]. Advantages of CEUS of the pancreas include high-detail resolution and real-time imaging, permitting visualization of intrapancreatic vessels and microvessels [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/18\" class=\"abstract_t\">18</a>]. The findings associated with specific pancreatic lesions are similar for both methods, but CE-EUS may permit visualization of a lesion that cannot be seen adequately with transcutaneous CEUS [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/18-21\" class=\"abstract_t\">18-21</a>].</p><p>The enhancement pattern of a focal pancreatic lesion is usually compared with the adjacent (healthy) pancreatic tissue. Healthy pancreatic parenchyma typically has a strong, homogenous enhancement pattern that begins immediately after aortic enhancement and lasts from 10 to 30 seconds (arterial phase). After the arterial phase, there is a transient venous phase that lasts from approximately 30 to 120 seconds after contrast injection [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/4,5\" class=\"abstract_t\">4,5</a>]. In patients with pancreatitis, the comparison of the enhancement pattern is more complicated because inflamed pancreatic tissue is hypervascular compared with healthy pancreatic tissue and areas of necrosis appear nonenhancing. </p><p class=\"headingAnchor\" id=\"H23450759\"><span class=\"h2\">Indications and efficacy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>CEUS in the pancreas is often used to differentiate pancreatic ductal adenocarcinoma from other solid tumors and to differentiate among pancreatic cystic lesions. For diagnosing malignancy, it has a sensitivity of approximately 90 percent and a specificity of 90 to 100 percent [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/22-24\" class=\"abstract_t\">22-24</a>].</p><p>CEUS can be used to [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/5,25\" class=\"abstract_t\">5,25</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Further evaluate a focal pancreatic lesion that is indeterminate on computed tomography (CT) or magnetic resonance imaging (MRI)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Characterize a solid pancreatic lesion as:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Pancreatic ductal adenocarcinoma</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A hyperenhancing solid pancreatic lesion (eg, a neuroendocrine tumor)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Mass-forming chronic pancreatitis</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Autoimmune pancreatitis</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Characterize a cystic lesion as:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A pseudocyst or walled-off pancreatic necrosis</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A serous cystadenoma</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A mucinous cystic neoplasm</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A mucinous cystadenocarcinoma</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>An intraductal papillary mucinous neoplasm (IPMN)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Identify areas of necrosis in acute pancreatitis</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Define the dimensions and margins of a neoplastic lesion, including its relationship with adjacent vessels, which is important for staging purposes and determining resectability</p><p/><p>One of the largest studies to look at the ability of CEUS to diagnose pancreatic lesions was the Pancreatic Multicenter Ultrasound Study [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/23\" class=\"abstract_t\">23</a>]. It included 1439 patients with pancreatic lesions. The findings on CEUS were compared with the final pathologic diagnoses. For solid lesions, the sensitivity for diagnosing adenocarcinoma was 88 percent and the specificity was 88 percent. The sensitivity and specificity for diagnosing a neuroendocrine tumor were 74 and 93 percent, respectively. For cystic lesions, the sensitivity for diagnosing a neoplasm was 78 percent and the specificity was 100 percent. Finally, the sensitivity and specificity for diagnosing a pseudocyst were 93 and 99 percent, respectively. In a second study that focused on cystic pancreatic lesions, CEUS had a sensitivity for diagnosing pseudocysts of 94 percent and a specificity of 77 percent [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/15\" class=\"abstract_t\">15</a>]. </p><p class=\"headingAnchor\" id=\"H63412672\"><span class=\"h2\">Solid lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most common solid primary pancreatic neoplasia is ductal adenocarcinoma [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/17\" class=\"abstract_t\">17</a>]. Pancreatic ductal adenocarcinoma is typically hypoenhancing in all phases, whereas other solid lesions, including neuroendocrine tumors, are hyperenhancing in the arterial phase.</p><p>In addition to enhancement patterns, other findings noted during CEUS can help diagnose a pancreatic ductal adenocarcinoma. One finding that helps differentiate ductal adenocarcinoma from other solid pancreatic lesions is dilation of the main pancreatic duct. It is often dilated in patients with ductal adenocarcinoma but not in pancreatic neuroendocrine tumors. Another feature associated with ductal adenocarcinoma is blurred mass margins (by contrast, they are sharply delineated in neuroendocrine tumors or in metastases from renal cell carcinoma). </p><p class=\"headingAnchor\" id=\"H63413077\"><span class=\"h3\">Ductal adenocarcinoma (hypoenhancing)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Because most ductal adenocarcinomas are characterized by a relatively low mean vascular density, they appear hypoenhancing in all phases (seen in approximately 90 percent of the cases) (<a href=\"image.htm?imageKey=GAST%2F97493\" class=\"graphic graphic_diagnosticimage graphicRef97493 \">image 1</a>) [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/17,26-28\" class=\"abstract_t\">17,26-28</a>]. This also applies to the very small, solid pancreatic lesions (ie, &le;15 mm) [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/29\" class=\"abstract_t\">29</a>].</p><p class=\"headingAnchor\" id=\"H63413084\"><span class=\"h3\">Hyperenhancing lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Unlike ductal adenocarcinomas, almost all other solid pancreatic lesions are hyperenhancing because they are hypervascular [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/22,24,26-28,30-32\" class=\"abstract_t\">22,24,26-28,30-32</a>]. These lesions include neuroendocrine tumors, serous microcystic neoplasia, hamartomas, focal pancreatitis, autoimmune pancreatitis, intrapancreatic accessory spleen, metastases, and other rare neoplasia and focal pancreatic lesions. </p><p class=\"headingAnchor\" id=\"H23450792\"><span class=\"h4\">Neuroendocrine tumors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Neuroendocrine tumors typically appear as focal pancreatic lesions that are well defined and hyperenhancing in the early arterial phase because of abundant arterial vascularization. The enhancement pattern is homogenous in small lesions, whereas larger lesions show a peripherally dominated pattern [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/22,24,33,34\" class=\"abstract_t\">22,24,33,34</a>]. In larger tumors, necrotic avascular areas lead to inhomogeneous enhancement (comparable to the findings in hepatic metastases) (<a href=\"image.htm?imageKey=GAST%2F97495\" class=\"graphic graphic_diagnosticimage graphicRef97495 \">image 2</a>) [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/35\" class=\"abstract_t\">35</a>]. There are also cystic forms of neuroendocrine tumors with variable appearances [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/36\" class=\"abstract_t\">36</a>]. </p><p>During the venous phase, rapid wash-out resulting in a hypoechoic appearance has been reported [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/33\" class=\"abstract_t\">33</a>]. Functioning neuroendocrine tumors are associated with endocrine symptoms. Such tumors are often smaller than 1.5 cm in 50 percent of the cases. This may be useful in differentiating them from solid pseudopapillary tumors, which are usually large and asymptomatic and present with characteristic peripheral rim isoenhancement [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/37\" class=\"abstract_t\">37</a>].</p><p class=\"headingAnchor\" id=\"H23450798\"><span class=\"h4\">Solid pseudopapillary tumors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Solid pseudopapillary tumors of the pancreas have patterns of enhancement that help differentiate them from other solid pancreatic tumors. Peripheral rim isoenhancement, internal heterogeneous enhancement with &quot;fast-in and fast-out&quot; enhancement, and nonenhancing zones due to necrotic and hemorrhagic areas are characteristic [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/38\" class=\"abstract_t\">38</a>]. The heterogeneous internal enhancement and the isoenhancing capsule are important diagnostic indicators of a solid pseudopapillary tumor because these features are rarely found in other pancreatic neoplasms [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/39\" class=\"abstract_t\">39</a>]. Sonographic contrast agents are blood pool agents that remain within the intravascular space. Due to this property, wash-out of solid pseudopapillary tumors during the venous phase can be seen with CEUS [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/33,40\" class=\"abstract_t\">33,40</a>]. By contrast, CT and MRI show a progressive fill-in due to the late enhancement of the fibrous tissue caused by rapid clearance of contrast agents from the intravascular space into the extravascular space. So, only CEUS can accurately show blood flow of these lesions, reflecting their vascular features. </p><p class=\"headingAnchor\" id=\"H23450804\"><span class=\"h4\">Nonfunctioning islet cell tumors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>These tumors are found more often in older adults, and they present on CEUS with rapid and intense hyperenhancement during the early arterial phase with nonenhancing necrotic areas [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/34\" class=\"abstract_t\">34</a>]. </p><p class=\"headingAnchor\" id=\"H23450810\"><span class=\"h2\">Cystic lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>CEUS can help differentiate pseudocysts and walled-off pancreatic necrosis (WOPN) from neoplastic cysts (eg, serous and mucinous cystadenomas, IPMNs). CEUS identifies areas that are perfused (septa, nodules) and areas that are nonperfused (debris, clots) [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/17\" class=\"abstract_t\">17</a>]. Cystic neoplasms typically show neovascularization of intralesional septa and parietal nodules, whereas pseudocysts and WOPN do not [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/15,19\" class=\"abstract_t\">15,19</a>]. Pseudocysts and WOPN typically contain nonvascularized, completely non-enhancing material (debris, clot) [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/5,41-43\" class=\"abstract_t\">5,41-43</a>]. However, in the early stages of pseudocyst formation, traversing (large) vessels may be seen that are hyperenhancing [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/17\" class=\"abstract_t\">17</a>]. The walls of pseudocysts may be highly vascularized if the cyst is &quot;young&quot; (few weeks of age) and poorly vascularized if the cyst is &quot;old&quot; (few months of age) [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/44\" class=\"abstract_t\">44</a>]. </p><p>CEUS findings associated with specific lesions include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Serous cystadenoma</strong> &ndash; Serous cystadenomas are composed of microcysts. They typically have a lobulated appearance with thin walls, centrally located arteries, and highly vascularized fibrotic septae with a spoke-like pattern [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/17,36\" class=\"abstract_t\">17,36</a>]. The vascularized areas are hyperenhancing on CEUS (<a href=\"image.htm?imageKey=GAST%2F97496\" class=\"graphic graphic_diagnosticimage graphicRef97496 \">image 3</a>). Small lesions can be confused with solid pancreatic lesions, including intrapancreatic accessory spleens, because of their abundant arterial vascularization [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/22,24,33,34\" class=\"abstract_t\">22,24,33,34</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Mucinous cystadenoma</strong> &ndash; Mucinous cystadenomas are macrocystic lesions with wall thickening, visible (enhancing) nodules and septae, and no duct involvement [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/36\" class=\"abstract_t\">36</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Mucinous cystadenocarcinoma</strong> &ndash; Mucinous cystadenocarcinomas consist of large cysts and solid areas that are poorly vascularized and thus hypoenhancing [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/44\" class=\"abstract_t\">44</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Intraductal papillary mucinous neoplasm (IPMN)</strong> &ndash; IPMNs are divided into main-duct and side-branch types [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/5\" class=\"abstract_t\">5</a>]. Main-duct IPMN has a characteristic endoscopic appearance (dilated pancreatic duct, fish-mouth papilla). Thus, their diagnosis typically does not require CEUS. If done, the appearance is one of irregular wall thickening and dilatation of the pancreatic duct (<a href=\"image.htm?imageKey=GAST%2F97497\" class=\"graphic graphic_diagnosticimage graphicRef97497 \">image 4</a>) [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/36\" class=\"abstract_t\">36</a>]. Side-branch IPMNs at an early stage often appear as small cystic lesions connected to the side branches of the main pancreatic duct (duct of Wirsung). More advanced side-branch IPMNs may have a grape-like configuration of small cysts and have additional findings, such as septae, nodules, and wall thickening.</p><p/><p class=\"bulletIndent1\">In the mixed-type IPMN, features of main pancreatic duct dilation and side branch cysts are combined.</p><p/><p class=\"headingAnchor\" id=\"H23450847\"><span class=\"h2\">Pancreatitis</span></p><p class=\"headingAnchor\" id=\"H23450854\"><span class=\"h3\">Acute pancreatitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In acute pancreatitis, organ failure and infected necrosis are the predominant prognostic features. CEUS can help identify necrotic areas since these areas do not enhance [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/44,45\" class=\"abstract_t\">44,45</a>]. In patients who require repeat imaging, CEUS is an attractive option because it does not have the radiation exposure associated with CT scanning. </p><p class=\"headingAnchor\" id=\"H325723028\"><span class=\"h3\">Chronic pancreatitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Early in the course of chronic pancreatitis, the pancreatic parenchyma may appear normal or hyperechoic because of fatty infiltration and fibrosis. With more advanced disease, it develops heterogenous echogenicity, and in addition, heterogeneous enhancement on CEUS. Other findings include irregular contour, intraductal and parenchymal calcifications, and pancreatic ductal dilation and strictures.</p><p class=\"headingAnchor\" id=\"H23450860\"><span class=\"h3\">Mass-forming pancreatitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Focal pancreatitis appears as a mass-like lesion that might be confused with neoplasia [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/30\" class=\"abstract_t\">30</a>]. It typically occurs in patients with a history of chronic pancreatitis. In patients with mass-forming pancreatitis, CEUS typically shows a similar or stronger enhancement pattern than the normal pancreatic parenchyma since both arterial and venous vessels are present (unlike ductal adenocarcinoma, which is typically hypoenhancing because only arterial vessels are present) [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/14\" class=\"abstract_t\">14</a>]. </p><p class=\"headingAnchor\" id=\"H23450873\"><span class=\"h3\">Autoimmune pancreatitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are three recognized patterns of autoimmune pancreatitis: diffuse, focal, and multifocal [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/46\" class=\"abstract_t\">46</a>]. Focal disease is often located within the pancreatic head and might mimic pancreatic malignancy [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/47\" class=\"abstract_t\">47</a>]. Both focal and diffuse autoimmune pancreatitis typically show hyperenhancement on CEUS or CE-EUS. CEUS contributes to the differentiation of hypoenhancing ductal adenocarcinoma from hyperenhancing focal autoimmune pancreatitis [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/48\" class=\"abstract_t\">48</a>]. For better visualization of vascular patterns, three-dimensional reconstruction might be useful [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/49\" class=\"abstract_t\">49</a>]. </p><p class=\"headingAnchor\" id=\"H23450885\"><span class=\"h1\">BILIARY TRACT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Contrast-enhanced ultrasound (CEUS) has been used for evaluation of the gallbladder and the biliary tree. CEUS can be used in the following clinical situations:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>To differentiate nonenhancing sludge and debris from enhancing neoplasia</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>To detect infiltration of surrounding structures by a tumor</p><p/><p class=\"headingAnchor\" id=\"H23450891\"><span class=\"h2\">Gallbladder</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>CEUS in the gallbladder and biliary tree is mainly helpful in differentiating nonenhancing sludge and debris from enhancing neoplasia [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/5\" class=\"abstract_t\">5</a>]. The vascular phases seen in the gallbladder wall are different from those of the liver because the blood supply is provided entirely by the cystic artery and not by portal vein branches [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/5,50\" class=\"abstract_t\">5,50</a>]. As a result, the arterial phase is followed directly by the venous phase [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/5\" class=\"abstract_t\">5</a>]. </p><p>CEUS has been used to detect gallbladder cancer and to detect complications of cholecystitis:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Gallbladder carcinomas are typically hyperenhancing in the arterial phase and hypoenhancing in the venous phase (<a href=\"image.htm?imageKey=GAST%2F97498\" class=\"graphic graphic_diagnosticimage graphicRef97498 \">image 5</a>). The absence of enhancement in biliary sludge allows differentiation from a tumor [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/5\" class=\"abstract_t\">5</a>]. In addition to suggesting a diagnosis of gallbladder carcinoma, CEUS can detect infiltration of the surrounding liver parenchyma or liver metastases [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/17\" class=\"abstract_t\">17</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with cholecystitis, interruption of the gallbladder wall suggests perforation. This can be confirmed by noting lack of enhancement of the perforated wall. CEUS can also be used to look for abscess formation in the adjacent liver parenchyma [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/51,52\" class=\"abstract_t\">51,52</a>]. </p><p/><p class=\"headingAnchor\" id=\"H23450909\"><span class=\"h2\">Biliary tree</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>CEUS may have a role in evaluating patients with cholangiocarcinoma. Promising findings have been observed in studies of patients with extrahepatic cholangiocarcinoma. CEUS (predominantly contrast-enhanced endoscopic ultrasound) has been able to determine the depth of tumor infiltration and to detect involvement of surrounding tissue [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/17,50,53\" class=\"abstract_t\">17,50,53</a>]. </p><p class=\"headingAnchor\" id=\"H23451115\"><span class=\"h1\">GASTROINTESTINAL TRACT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the gastrointestinal tract, contrast-enhanced ultrasound (CEUS) has primarily been used to evaluate the bowel wall and peri-intestinal structures. In addition, extravascular (intracavitary) use has been described. The normal gastrointestinal wall measures less than 2 mm in thickness and shows homogenous contrast enhancement [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/54\" class=\"abstract_t\">54</a>]. For gastrointestinal tract examination, higher frequency transducers (7.5 MHz) and higher contrast doses (eg, 2.4 to 4.8 mL) are used. The arterial phase lasts until 30 to 40 seconds after injection, when peak enhancement is reached. Then, a venous phase follows, lasting until approximately 120 seconds [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/5,55\" class=\"abstract_t\">5,55</a>]. </p><p class=\"headingAnchor\" id=\"H23451135\"><span class=\"h2\">Inflammatory bowel disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with inflammatory bowel disease (IBD), CEUS is helpful in distinguishing abscesses from (peri-) intestinal vascularized inflammatory masses, including fistulas (<a href=\"image.htm?imageKey=GAST%2F97499\" class=\"graphic graphic_diagnosticimage graphicRef97499 \">image 6</a>) [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/5,17,56,57\" class=\"abstract_t\">5,17,56,57</a>]. CEUS can also help distinguish between fibrous and inflammatory strictures since active inflammation enhances strongly, whereas a fibrotic stricture enhances poorly [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/58\" class=\"abstract_t\">58</a>]. However, in the United States and United Kingdom, evaluation with computed tomography or magnetic resonance imaging (MRI) is more commonly performed for the evaluation of IBD.</p><p>CEUS can be used to study disease activity in IBD, using bowel wall thickness and CEUS enhancement as markers of inflammation, but the role of CEUS for treatment initiation and monitoring has not yet been determined [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/57\" class=\"abstract_t\">57</a>]. The use of an oral anechoic contrast solution (iso-osmolar polyethylene glycol) enhances the ability of CEUS to evaluate inflammatory activity and decreases the interobserver variability [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/59-61\" class=\"abstract_t\">59-61</a>]. </p><p>CEUS can be used in the following clinical situations:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Differentiating between a fistula and abscess</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Estimation of disease activity in IBD</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Discerning between fibrous and inflammatory strictures in Crohn disease </p><p/><p>CEUS has been used to quantify bowel wall vascularity, which is considered to be a marker of inflammatory activity in patients with Crohn disease [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/62\" class=\"abstract_t\">62</a>]. Enhancement in different wall layers can be evaluated and quantified and correlates well with clinical activity indices [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/62-64\" class=\"abstract_t\">62-64</a>] and with MRI findings [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/65,66\" class=\"abstract_t\">65,66</a>]. Time-intensity curve analysis (contrast kinetics) may further quantify disease activity [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/5\" class=\"abstract_t\">5</a>]. In a study with 104 patients with Crohn disease examined by CEUS with respect to the disease activity index, it was found that the pattern of contrast enhancement and the ratio of enhanced to entire wall thickness had a sensitivity of 81 percent and a specificity of 63 percent for detecting active disease [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/62\" class=\"abstract_t\">62</a>]. </p><p>In a second study with 105 patients with Crohn disease, CEUS was compared with magnetic resonance enterography (MRE) for detecting terminal ileal inflammation (using ileoscopy as the gold standard for assessing disease activity) [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/67\" class=\"abstract_t\">67</a>]. CEUS was technically feasible in 98 percent of patients and MRE in 100 percent. CEUS was more sensitive than MRE (100 versus 87 percent), with similar specificity (92 versus 100 percent) for detecting active inflammation in the terminal ileum. MRE detected 16 ileal strictures and five fistulas. CEUS identified 11 of the strictures but none of the fistulas.</p><p>CEUS may also provide prognostic data in patients receiving biologic therapies [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/68\" class=\"abstract_t\">68</a>], but this has not yet been evaluated in detail. </p><p class=\"headingAnchor\" id=\"H23451147\"><span class=\"h2\">Neoplasia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A role for CEUS in the diagnosis of gastrointestinal cancer has not been established [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/69,70\" class=\"abstract_t\">69,70</a>]. Gastrointestinal stromal tumors (GISTs) and other subepithelial lesions show typical arterial hyperenhancement [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/71\" class=\"abstract_t\">71</a>]. Enhancement of small GISTs (&lt;20 mm) and larger low-risk GISTs may be homogeneous, whereas almost all malignant GISTs show heterogeneous enhancement and avascular areas, independent of their size. Central necrosis may be seen in GISTs using CEUS and contrast-enhanced endoscopic ultrasound. Central necrosis is often not seen with other subepithelial lesions (eg, leiomyoma, schwannoma), which show homogeneous enhancement. </p><p class=\"headingAnchor\" id=\"H23451171\"><span class=\"h1\">EXTRAVASCULAR CONTRAST ADMINISTRATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Numerous reports on extravascular or intracavitary administration of ultrasound contrast agents have been published, but large prospective studies are lacking [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/72-74\" class=\"abstract_t\">72-74</a>]. The contrast agent can be injected into physiologic cavities (eg, the gallbladder) or into non-physiologic spaces such as fistulas. The examination of the course of fistulas in Crohn disease is a typical extravascular application. </p><p class=\"headingAnchor\" id=\"H12521071\"><span class=\"h2\">Uses</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Extravascular contrast-enhanced ultrasound (CEUS) can be used in the following clinical situations:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Differentiating between a fistula and abscess</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Assisting in interventional procedures (eg, abscess drainage) [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/75\" class=\"abstract_t\">75</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Determining the route of a fistula</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diagnosing Zenker's diverticulum [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/76\" class=\"abstract_t\">76</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diagnosing hepatic hydrothorax</p><p/><p>CEUS has been used to diagnose rectovaginal fistulas (via a transvaginal approach) [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/77\" class=\"abstract_t\">77</a>], vesicointestinal fistulas (via a transabdominal approach) [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/78\" class=\"abstract_t\">78</a>], and anal fistulas (via a transrectal approach) [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/79\" class=\"abstract_t\">79</a>]. It has also been used to assist pseudocyst drainage using endoscopic ultrasound [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/75\" class=\"abstract_t\">75</a>].</p><p>In addition to diagnosing abscesses, the combined use of intravenous and intracavitary CEUS can guide abscess treatment. Contrast agents are given intravenously for better delineation of the abscess and are injected into the abscess cavity during intervention to detect communication between septated cavities. The combined approach is also used for follow-up examinations to evaluate the treatment response and detect complications [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/5,75\" class=\"abstract_t\">5,75</a>].</p><p>Other clinical applications include evaluation of diverticula, gastroesophageal reflux disease, bile ducts, and intestinal stenosis. Functional ultrasound (eg, determining gastric emptying) can also be performed using intraluminal contrast [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/80\" class=\"abstract_t\">80</a>]. Extravascular CEUS is most commonly used in settings when standard diagnostic techniques are inconclusive, not suitable for a particular patient, are associated with high risk (eg, moving a patient out of an intensive care unit), or are not available [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/81\" class=\"abstract_t\">81</a>].</p><p class=\"headingAnchor\" id=\"H63414997\"><span class=\"h2\">Technique</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>No standard dose of ultrasound contrast agent has been established for intracavitary (extravascular) injection. The range of reported doses is 0.1 mL to 1 mL (most commonly just a few drops) diluted in 10 mL or more of 0.9 percent saline; a higher content of contrast agent may be needed for high-frequency ultrasound probes (eg, those used for contrast-enhanced endoscopic ultrasound) [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/3,82\" class=\"abstract_t\">3,82</a>]. </p><p>If the aim of the investigation is to detect a connection between two cavities (eg, when evaluating fistulas or diagnosing hepatic hydrothorax), a dose of 1 to 2 mL appears to be effective. If the aim of the investigation is to demonstrate the exact anatomy of a cavity, a lower dose must be given to avoid shadowing that may result in poor image quality and missing or false information [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/83,84\" class=\"abstract_t\">83,84</a>]. One suggested dose in this setting is 0.1 mL of the ultrasound contrast agent in 20 mL saline [<a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/82\" class=\"abstract_t\">82</a>]. </p><p class=\"headingAnchor\" id=\"H63415004\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Contrast-enhanced ultrasound (CEUS) is a well-established technique for imaging the liver and other organs. It is used in most of Europe and Asia, and in many other countries worldwide. The contrast agent used for CEUS of the liver has also been approved by the US Food and Drug Administration. (See <a href=\"#H20842311\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CEUS uses ultrasound contrast agents to improve visualization and characterization of anatomic structures and lesions. CEUS permits real-time visualization of contrast-enhancement patterns during the arterial and venous phases, and in the case of the liver, the portal-venous phase. (See <a href=\"topic.htm?path=contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions#H92235607\" class=\"medical medical_review\">&quot;Contrast-enhanced ultrasound for the evaluation of liver lesions&quot;, section on 'General principles'</a> and <a href=\"topic.htm?path=contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions#H60340511\" class=\"medical medical_review\">&quot;Contrast-enhanced ultrasound for the evaluation of liver lesions&quot;, section on 'Advantages of CEUS'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CEUS in the pancreas is often used to differentiate pancreatic ductal adenocarcinoma from other solid tumors, such as neuroendocrine tumors. It is also used to differentiate pancreatic cystic lesions (eg, intraductal papillary mucinous tumors, mucinous cystadenomas, serous cystadenomas, organized pancreatic necrosis, and pseudocysts). (See <a href=\"#H20842323\" class=\"local\">'Pancreas'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the gallbladder and biliary tree, CEUS has been used in the following clinical situations (see <a href=\"#H23450885\" class=\"local\">'Biliary tract'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>To differentiate non-enhancing sludge and debris from enhancing neoplasia</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>To detect infiltration of surrounding structures by a tumor</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with inflammatory bowel disease (IBD), CEUS can help to distinguish abscesses from (peri-) intestinal vascularized inflammatory masses, including fistulas. CEUS can also help characterize fibrous versus inflammatory strictures since active inflammation enhances strongly, whereas a fibrotic stricture enhances poorly. (See <a href=\"#H23451115\" class=\"local\">'Gastrointestinal tract'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In extravascular CEUS, the contrast agent is injected into physiologic cavities (eg, the gallbladder) or into non-physiologic spaces and fistulas. Extravascular CEUS can be used in the following clinical situations (see <a href=\"#H23451171\" class=\"local\">'Extravascular contrast administration'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Differentiating between a fistula and abscess</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Determining the route of a fistula</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Diagnosing hepatic hydrothorax</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/1\" class=\"nounderline abstract_t\">Claudon M, Dietrich CF, Choi BI, et al. Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol 2013; 39:187.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/2\" class=\"nounderline abstract_t\">Claudon M, Dietrich CF, Choi BI, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver--update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultraschall Med 2013; 34:11.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/3\" class=\"nounderline abstract_t\">Albrecht T, Blomley M, Bolondi L, et al. Guidelines for the use of contrast agents in ultrasound. January 2004. Ultraschall Med 2004; 25:249.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/4\" class=\"nounderline abstract_t\">Claudon M, Cosgrove D, Albrecht T, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) - update 2008. Ultraschall Med 2008; 29:28.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/5\" class=\"nounderline abstract_t\">Piscaglia F, Nols&oslash;e C, Dietrich CF, et al. The EFSUMB Guidelines and Recommendations on the Clinical Practice of Contrast Enhanced Ultrasound (CEUS): update 2011 on non-hepatic applications. Ultraschall Med 2012; 33:33.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/6\" class=\"nounderline abstract_t\">Dietrich CF, Averkiou MA, Correas JM, et al. An EFSUMB introduction into Dynamic Contrast-Enhanced Ultrasound (DCE-US) for quantification of tumour perfusion. Ultraschall Med 2012; 33:344.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/7\" class=\"nounderline abstract_t\">Nylund K, Maconi G, Hollerweger A, et al.. EFSUMB Recommendations and Guidelines for Gastrointestinal Ultrasound - Part 1: Examination Techniques and Normal Findings (Long version). Ultraschall Med 2016.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/8\" class=\"nounderline abstract_t\">Nylund K, Maconi G, Hollerweger A, et al.. EFSUMB Recommendations and Guidelines for Gastrointestinal Ultrasound - Part 1: Examination Techniques and Normal Findings (Short version). Ultraschall Med 2016.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/9\" class=\"nounderline abstract_t\">Kono Y, Lyshchik A, Cosgrove D, et al. Contrast Enhanced Ultrasound (CEUS) Liver Imaging Reporting and Data System (LI-RADS&reg;): the official version by the American College of Radiology (ACR). Ultraschall Med 2017; 38:85.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/10\" class=\"nounderline abstract_t\">Wilson SR, Greenbaum LD, Goldberg BB. Contrast-enhanced ultrasound: what is the evidence and what are the obstacles? AJR Am J Roentgenol 2009; 193:55.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/11\" class=\"nounderline abstract_t\">Jang JY, Kim MY, Jeong SW, et al. Current consensus and guidelines of contrast enhanced ultrasound for the characterization of focal liver lesions. Clin Mol Hepatol 2013; 19:1.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/12\" class=\"nounderline abstract_t\">Becker D, Strobel D, Bernatik T, Hahn EG. Echo-enhanced color- and power-Doppler EUS for the discrimination between focal pancreatitis and pancreatic carcinoma. Gastrointest Endosc 2001; 53:784.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/13\" class=\"nounderline abstract_t\">Bhutani MS, Hoffman BJ, van Velse A, Hawes RH. Contrast-enhanced endoscopic ultrasonography with galactose microparticles: SHU508 A (Levovist). Endoscopy 1997; 29:635.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/14\" class=\"nounderline abstract_t\">Hocke M, Schulze E, Gottschalk P, et al. Contrast-enhanced endoscopic ultrasound in discrimination between focal pancreatitis and pancreatic cancer. World J Gastroenterol 2006; 12:246.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/15\" class=\"nounderline abstract_t\">Beyer-Enke SA, Hocke M, Ignee A, et al. Contrast enhanced transabdominal ultrasound in the characterisation of pancreatic lesions with cystic appearance. JOP 2010; 11:427.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/16\" class=\"nounderline abstract_t\">Dietrich CF. Contrast-enhanced low mechanical index endoscopic ultrasound (CELMI-EUS). Endoscopy 2009; 41 Suppl 2:E43.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/17\" class=\"nounderline abstract_t\">Dietrich CF, Cui XW, Schreiber-Dietrich DG, Ignee A. EFSUMB guidelines 2011: comments and illustrations. Ultraschall Med 2012; 33 Suppl 1:S11.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/18\" class=\"nounderline abstract_t\">D'Onofrio M, Malag&ograve; R, Zamboni G, et al. Contrast-enhanced ultrasonography better identifies pancreatic tumor vascularization than helical CT. Pancreatology 2005; 5:398.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/19\" class=\"nounderline abstract_t\">D'Onofrio M, Megibow AJ, Faccioli N, et al. Comparison of contrast-enhanced sonography and MRI in displaying anatomic features of cystic pancreatic masses. AJR Am J Roentgenol 2007; 189:1435.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/20\" class=\"nounderline abstract_t\">Faccioli N, D'Onofrio M, Malag&ograve; R, et al. Resectable pancreatic adenocarcinoma: depiction of tumoral margins at contrast-enhanced ultrasonography. Pancreas 2008; 37:265.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/21\" class=\"nounderline abstract_t\">Numata K, Ozawa Y, Kobayashi N, et al. Contrast-enhanced sonography of pancreatic carcinoma: correlations with pathological findings. J Gastroenterol 2005; 40:631.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/22\" class=\"nounderline abstract_t\">Dietrich CF, Braden B, Hocke M, et al. Improved characterisation of solitary solid pancreatic tumours using contrast enhanced transabdominal ultrasound. J Cancer Res Clin Oncol 2008; 134:635.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/23\" class=\"nounderline abstract_t\">D'Onofrio M, Barbi E, Dietrich CF, et al. Pancreatic multicenter ultrasound study (PAMUS). Eur J Radiol 2012; 81:630.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/24\" class=\"nounderline abstract_t\">Dietrich CF, Ignee A, Braden B, et al. Improved differentiation of pancreatic tumors using contrast-enhanced endoscopic ultrasound. Clin Gastroenterol Hepatol 2008; 6:590.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/25\" class=\"nounderline abstract_t\">Dietrich CF, Schreiber-Dietrich D, Hocke M. [Comments on the EFSUMB non-liver Guidelines 2011]. Praxis (Bern 1994) 2012; 101:1175.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/26\" class=\"nounderline abstract_t\">M&auml;kinen K, Loimas S, Nuutinen P, et al. The growth pattern and microvasculature of pancreatic tumours induced with cultured carcinoma cells. Br J Cancer 2000; 82:900.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/27\" class=\"nounderline abstract_t\">Ryschich E, Schmidt E, Maksan SM, et al. Expansion of endothelial surface by an increase of vessel diameter during tumor angiogenesis in experimental and hepatocellular and pancreatic cancer. World J Gastroenterol 2004; 10:3171.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/28\" class=\"nounderline abstract_t\">Schmidt J, Ryschich E, Daniel V, et al. Vascular structure and microcirculation of experimental pancreatic carcinoma in rats. Eur J Surg 2000; 166:328.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/29\" class=\"nounderline abstract_t\">Dietrich CF, Sahai AV, D'Onofrio M, et al. Differential diagnosis of small solid pancreatic lesions. Gastrointest Endosc 2016; 84:933.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/30\" class=\"nounderline abstract_t\">D'Onofrio M, Zamboni G, Tognolini A, et al. Mass-forming pancreatitis: value of contrast-enhanced ultrasonography. World J Gastroenterol 2006; 12:4181.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/31\" class=\"nounderline abstract_t\">Kersting S, Konopke R, Kersting F, et al. Quantitative perfusion analysis of transabdominal contrast-enhanced ultrasonography of pancreatic masses and carcinomas. Gastroenterology 2009; 137:1903.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/32\" class=\"nounderline abstract_t\">Ryschich E, Schmidt J, Loeffler T, et al. Different radiogenic effects on microcirculation in healthy pancreas and in pancreatic carcinoma of the rat. Ann Surg 2003; 237:515.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/33\" class=\"nounderline abstract_t\">D'Onofrio M, Mansueto G, Falconi M, Procacci C. Neuroendocrine pancreatic tumor: value of contrast enhanced ultrasonography. Abdom Imaging 2004; 29:246.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/34\" class=\"nounderline abstract_t\">Malag&ograve; R, D'Onofrio M, Zamboni GA, et al. Contrast-enhanced sonography of nonfunctioning pancreatic neuroendocrine tumors. AJR Am J Roentgenol 2009; 192:424.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/35\" class=\"nounderline abstract_t\">M&ouml;rk H, Ignee A, Schuessler G, et al. Analysis of neuroendocrine tumour metastases in the liver using contrast enhanced ultrasonography. Scand J Gastroenterol 2007; 42:652.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/36\" class=\"nounderline abstract_t\">Hocke M, Cui XW, Domagk D, et al. Pancreatic cystic lesions: The value of contrast-enhanced endoscopic ultrasound to influence the clinical pathway. Endosc Ultrasound 2014; 3:123.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/37\" class=\"nounderline abstract_t\">Ros PR, Mortel&eacute; KJ. Imaging features of pancreatic neoplasms. JBR-BTR 2001; 84:239.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/38\" class=\"nounderline abstract_t\">Tang SS, Huang LP, Wang Y, Ma Y. Solid pseudopapillary tumors of the pancreas: contrast-enhanced sonographic features. J Ultrasound Med 2012; 31:257.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/39\" class=\"nounderline abstract_t\">Cantisani V, Mortele KJ, Levy A, et al. MR imaging features of solid pseudopapillary tumor of the pancreas in adult and pediatric patients. AJR Am J Roentgenol 2003; 181:395.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/40\" class=\"nounderline abstract_t\">Faccioli N, Crippa S, Bassi C, D'Onofrio M. Contrast-enhanced ultrasonography of the pancreas. Pancreatology 2009; 9:560.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/41\" class=\"nounderline abstract_t\">Seicean A, Badea R, Stan-Iuga R, et al. The added value of real-time harmonics contrast-enhanced endoscopic ultrasonography for the characterisation of pancreatic diseases in routine practice. J Gastrointestin Liver Dis 2010; 19:99.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/42\" class=\"nounderline abstract_t\">Sakamoto H, Kitano M, Kamata K, et al. Diagnosis of pancreatic tumors by endoscopic ultrasonography. World J Radiol 2010; 2:122.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/43\" class=\"nounderline abstract_t\">Ohno E, Itoh A, Kawashima H, et al. Malignant transformation of branch duct-type intraductal papillary mucinous neoplasms of the pancreas based on contrast-enhanced endoscopic ultrasonography morphological changes: focus on malignant transformation of intraductal papillary mucinous neoplasm itself. Pancreas 2012; 41:855.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/44\" class=\"nounderline abstract_t\">Rickes S, Rauh P, Uhle C, et al. Contrast-enhanced sonography in pancreatic diseases. Eur J Radiol 2007; 64:183.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/45\" class=\"nounderline abstract_t\">Ripoll&eacute;s T, Mart&iacute;nez MJ, L&oacute;pez E, et al. Contrast-enhanced ultrasound in the staging of acute pancreatitis. Eur Radiol 2010; 20:2518.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/46\" class=\"nounderline abstract_t\">Dong Y, D'Onofrio M, Hocke M, et al. Autoimmune pancreatitis: Imaging features. Endosc Ultrasound 2017.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/47\" class=\"nounderline abstract_t\">Crosara S, D'Onofrio M, De Robertis R, et al. Autoimmune pancreatitis: Multimodality non-invasive imaging diagnosis. World J Gastroenterol 2014; 20:16881.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/48\" class=\"nounderline abstract_t\">Mauch M, Blank W, Kunze G, et al. Importance of Abdominal Ultrasound in 17 Patients with Histologically Confirmed Autoimmune Pancreatitis (AIP). Ultraschall Med 2015; 36:248.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/49\" class=\"nounderline abstract_t\">Hocke M, Ignee A, Dietrich CF. Contrast-enhanced endoscopic ultrasound in the diagnosis of autoimmune pancreatitis. Endoscopy 2011; 43:163.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/50\" class=\"nounderline abstract_t\">Cui XW, Ignee A, Braden B, et al. Biliary papillomatosis and new ultrasound imaging modalities. Z Gastroenterol 2012; 50:226.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/51\" class=\"nounderline abstract_t\">Dietrich CF, Maddalena ME, Cui XW, et al. Liver tumor characterization--review of the literature. Ultraschall Med 2012; 33 Suppl 1:S3.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/52\" class=\"nounderline abstract_t\">Dietrich CF. Liver tumor characterization--comments and illustrations regarding guidelines. Ultraschall Med 2012; 33 Suppl 1:S22.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/53\" class=\"nounderline abstract_t\">Barreiros AP, Piscaglia F, Dietrich CF. Contrast enhanced ultrasound for the diagnosis of hepatocellular carcinoma (HCC): comments on AASLD guidelines. J Hepatol 2012; 57:930.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/54\" class=\"nounderline abstract_t\">&Oslash;degaard S, Nesje LB, L&aelig;rum OD, Kimmey MB. High-frequency ultrasonographic imaging of the gastrointestinal wall. Expert Rev Med Devices 2012; 9:263.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/55\" class=\"nounderline abstract_t\">Plikat K, Klebl F, Buchner C, et al. [Evaluation of intestinal hyperaemia in inflamed bowel by high resolution Contrast Harmonic Imaging (CHI)]. Ultraschall Med 2004; 25:257.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/56\" class=\"nounderline abstract_t\">Dietrich CF. Significance of abdominal ultrasound in inflammatory bowel disease. Dig Dis 2009; 27:482.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/57\" class=\"nounderline abstract_t\">Dietrich CF, Jedrzejczyk M, Ignee A. Sonographic assessment of splanchnic arteries and the bowel wall. Eur J Radiol 2007; 64:202.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/58\" class=\"nounderline abstract_t\">Wilson SR, Burns PN. Microbubble-enhanced US in body imaging: what role? Radiology 2010; 257:24.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/59\" class=\"nounderline abstract_t\">Levine A, Koletzko S, Turner D, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 2014; 58:795.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/60\" class=\"nounderline abstract_t\">Pallotta N, Tomei E, Viscido A, et al. Small intestine contrast ultrasonography: an alternative to radiology in the assessment of small bowel disease. Inflamm Bowel Dis 2005; 11:146.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/61\" class=\"nounderline abstract_t\">Migaleddu V, Quaia E, Scanu D, et al. Inflammatory activity in Crohn's disease: CE-US. Abdom Imaging 2011; 36:142.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/62\" class=\"nounderline abstract_t\">Serra C, Menozzi G, Labate AM, et al. Ultrasound assessment of vascularization of the thickened terminal ileum wall in Crohn's disease patients using a low-mechanical index real-time scanning technique with a second generation ultrasound contrast agent. Eur J Radiol 2007; 62:114.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/63\" class=\"nounderline abstract_t\">Migaleddu V, Scanu AM, Quaia E, et al. Contrast-enhanced ultrasonographic evaluation of inflammatory activity in Crohn's disease. Gastroenterology 2009; 137:43.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/64\" class=\"nounderline abstract_t\">Girlich C, Schacherer D, Jung EM, et al. Comparison between a clinical activity index (Harvey-Bradshaw-Index), laboratory inflammation markers and quantitative assessment of bowel wall vascularization by contrast-enhanced ultrasound in Crohn's disease. Eur J Radiol 2012; 81:1105.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/65\" class=\"nounderline abstract_t\">Schreyer AG, Finkenzeller T, G&ouml;ssmann H, et al. Microcirculation and perfusion with contrast enhanced ultrasound (CEUS) in Crohn's disease: first results with linear contrast harmonic imaging (CHI). Clin Hemorheol Microcirc 2008; 40:143.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/66\" class=\"nounderline abstract_t\">Pauls S, Gabelmann A, Schmidt SA, et al. Evaluating bowel wall vascularity in Crohn's disease: a comparison of dynamic MRI and wideband harmonic imaging contrast-enhanced low MI ultrasound. Eur Radiol 2006; 16:2410.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/67\" class=\"nounderline abstract_t\">Horjus Talabur Horje CS, Bruijnen R, Roovers L, et al. Contrast Enhanced Abdominal Ultrasound in the Assessment of Ileal Inflammation in Crohn's Disease: A Comparison with MR Enterography. PLoS One 2015; 10:e0136105.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/68\" class=\"nounderline abstract_t\">Guidi L, De Franco A, De Vitis I, et al. Contrast-enhanced ultrasonography with SonoVue after infliximab therapy in Crohn's disease. Eur Rev Med Pharmacol Sci 2006; 10:23.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/69\" class=\"nounderline abstract_t\">Dietrich CF, Jenssen C, Hocke M, et al. Imaging of gastrointestinal stromal tumours with modern ultrasound techniques - a pictorial essay. Z Gastroenterol 2012; 50:457.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/70\" class=\"nounderline abstract_t\">Sakamoto H, Kitano M, Matsui S, et al. Estimation of malignant potential of GI stromal tumors by contrast-enhanced harmonic EUS (with videos). Gastrointest Endosc 2011; 73:227.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/71\" class=\"nounderline abstract_t\">Dietrich CF, Jenssen C. [Evidence based endoscopic ultrasound]. Z Gastroenterol 2011; 49:599.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/72\" class=\"nounderline abstract_t\">Duran C, Valera A, Alguersuari A, et al. Voiding urosonography: the study of the urethra is no longer a limitation of the technique. Pediatr Radiol 2009; 39:124.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/73\" class=\"nounderline abstract_t\">Darge K. Voiding urosonography with ultrasound contrast agents for the diagnosis of vesicoureteric reflux in children. I. Procedure. Pediatr Radiol 2008; 38:40.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/74\" class=\"nounderline abstract_t\">Darge K. Voiding urosonography with US contrast agents for the diagnosis of vesicoureteric reflux in children. II. Comparison with radiological examinations. Pediatr Radiol 2008; 38:54.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/75\" class=\"nounderline abstract_t\">Ignee A, Jenssen C, Cui XW, et al. Intracavitary contrast-enhanced ultrasound in abscess drainage--feasibility and clinical value. Scand J Gastroenterol 2016; 51:41.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/76\" class=\"nounderline abstract_t\">Cui XW, Ignee A, Baum U, Dietrich CF. Feasibility and usefulness of using swallow contrast-enhanced ultrasound to diagnose Zenker's diverticulum: preliminary results. Ultrasound Med Biol 2015; 41:975.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/77\" class=\"nounderline abstract_t\">Henrich W, Meckies J, Friedmann W. Demonstration of a recto-vaginal fistula with the ultrasound contrast medium Echovist. Ultrasound Obstet Gynecol 2000; 15:148.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/78\" class=\"nounderline abstract_t\">Volkmer BG, Nesslauer T, K&uuml;fer R, et al. [Diagnosis of vesico-intestinal fistulas by contrast medium enhanced 3-D ultrasound]. Ultraschall Med 2001; 22:81.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/79\" class=\"nounderline abstract_t\">Chew SS, Yang JL, Newstead GL, Douglas PR. Anal fistula: Levovist-enhanced endoanal ultrasound: a pilot study. Dis Colon Rectum 2003; 46:377.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/80\" class=\"nounderline abstract_t\">Nuernberg D, Braden B, Ignee A, et al. [Functional ultrasound in gastroenterology]. Z Gastroenterol 2008; 46:883.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/81\" class=\"nounderline abstract_t\">Dietrich CF, Cui XW, Barreiros AP, et al. EFSUMB guidelines 2011: comment on emergent indications and visions. Ultraschall Med 2012; 33 Suppl 1:S39.</a></li><li class=\"breakAll\">Ignee A, Schuessler G, Dietrich CF. Extravaskul&auml;re Applikation von Ultraschallkontrastmitteln. In: Interventionelle Sonographie, Dietrich CF, N&uuml;rnberg D (Eds), Georg Thieme Verlag KG Stuttgart, New York 2011. p.514.</li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/83\" class=\"nounderline abstract_t\">Ignee A, Baum U, Schuessler G, Dietrich CF. Contrast-enhanced ultrasound-guided percutaneous cholangiography and cholangiodrainage (CEUS-PTCD). Endoscopy 2009; 41:725.</a></li><li><a href=\"https://www.uptodate.com/contents/contrast-enhanced-ultrasound-gastrointestinal-applications-outside-of-the-liver/abstract/84\" class=\"nounderline abstract_t\">Dietrich CF, Ignee A, Greis C, et al. Artifacts and pitfalls in contrast-enhanced ultrasound of the liver. Ultraschall Med 2014; 35:108.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 96777 Version 6.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H63415004\"><span>SUMMARY</span></a></li><li><a href=\"#H20842311\" id=\"outline-link-H20842311\">INTRODUCTION</a></li><li><a href=\"#H20842317\" id=\"outline-link-H20842317\">GENERAL PRINCIPLES</a></li><li><a href=\"#H63411422\" id=\"outline-link-H63411422\">TECHNICAL ASPECTS</a><ul><li><a href=\"#H63411985\" id=\"outline-link-H63411985\">Transcutaneous contrast-enhanced ultrasound</a></li><li><a href=\"#H63411624\" id=\"outline-link-H63411624\">Contrast-enhanced endoscopic ultrasound</a></li><li><a href=\"#H12520289\" id=\"outline-link-H12520289\">Contrast agent dosing</a></li></ul></li><li><a href=\"#H20842323\" id=\"outline-link-H20842323\">PANCREAS</a><ul><li><a href=\"#H23450759\" id=\"outline-link-H23450759\">Indications and efficacy</a></li><li><a href=\"#H63412672\" id=\"outline-link-H63412672\">Solid lesions</a><ul><li><a href=\"#H63413077\" id=\"outline-link-H63413077\">- Ductal adenocarcinoma (hypoenhancing)</a></li><li><a href=\"#H63413084\" id=\"outline-link-H63413084\">- Hyperenhancing lesions</a><ul><li><a href=\"#H23450792\" id=\"outline-link-H23450792\">Neuroendocrine tumors</a></li><li><a href=\"#H23450798\" id=\"outline-link-H23450798\">Solid pseudopapillary tumors</a></li><li><a href=\"#H23450804\" id=\"outline-link-H23450804\">Nonfunctioning islet cell tumors</a></li></ul></li></ul></li><li><a href=\"#H23450810\" id=\"outline-link-H23450810\">Cystic lesions</a></li><li><a href=\"#H23450847\" id=\"outline-link-H23450847\">Pancreatitis</a><ul><li><a href=\"#H23450854\" id=\"outline-link-H23450854\">- Acute pancreatitis</a></li><li><a href=\"#H325723028\" id=\"outline-link-H325723028\">- Chronic pancreatitis</a></li><li><a href=\"#H23450860\" id=\"outline-link-H23450860\">- Mass-forming pancreatitis</a></li><li><a href=\"#H23450873\" id=\"outline-link-H23450873\">- Autoimmune pancreatitis</a></li></ul></li></ul></li><li><a href=\"#H23450885\" id=\"outline-link-H23450885\">BILIARY TRACT</a><ul><li><a href=\"#H23450891\" id=\"outline-link-H23450891\">Gallbladder</a></li><li><a href=\"#H23450909\" id=\"outline-link-H23450909\">Biliary tree</a></li></ul></li><li><a href=\"#H23451115\" id=\"outline-link-H23451115\">GASTROINTESTINAL TRACT</a><ul><li><a href=\"#H23451135\" id=\"outline-link-H23451135\">Inflammatory bowel disease</a></li><li><a href=\"#H23451147\" id=\"outline-link-H23451147\">Neoplasia</a></li></ul></li><li><a href=\"#H23451171\" id=\"outline-link-H23451171\">EXTRAVASCULAR CONTRAST ADMINISTRATION</a><ul><li><a href=\"#H12521071\" id=\"outline-link-H12521071\">Uses</a></li><li><a href=\"#H63414997\" id=\"outline-link-H63414997\">Technique</a></li></ul></li><li><a href=\"#H63415004\" id=\"outline-link-H63415004\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"GAST/96777|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/97493\" class=\"graphic graphic_diagnosticimage\">- Pancreatic adenocarcinoma CEUS</a></li><li><a href=\"image.htm?imageKey=GAST/97495\" class=\"graphic graphic_diagnosticimage\">- Pancreatic neuroendocrine tumor CEUS</a></li><li><a href=\"image.htm?imageKey=GAST/97496\" class=\"graphic graphic_diagnosticimage\">- Pancreatic serous cystadenoma CEUS</a></li><li><a href=\"image.htm?imageKey=GAST/97497\" class=\"graphic graphic_diagnosticimage\">- Main duct IPMN CEUS</a></li><li><a href=\"image.htm?imageKey=GAST/97498\" class=\"graphic graphic_diagnosticimage\">- Gallbladder neoplasia CEUS</a></li><li><a href=\"image.htm?imageKey=GAST/97499\" class=\"graphic graphic_diagnosticimage\">- Intestinal abscess fistula CEUS</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=contrast-echocardiography-clinical-applications\" class=\"medical medical_review\">Contrast echocardiography: Clinical applications</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=contrast-echocardiography-contrast-agents-safety-and-imaging-technique\" class=\"medical medical_review\">Contrast echocardiography: Contrast agents, safety, and imaging technique</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=contrast-enhanced-ultrasound-for-the-evaluation-of-liver-lesions\" class=\"medical medical_review\">Contrast-enhanced ultrasound for the evaluation of liver lesions</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=endoscopic-ultrasound-in-chronic-pancreatitis\" class=\"medical medical_review\">Endoscopic ultrasound in chronic pancreatitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=endoscopic-ultrasound-in-the-staging-of-exocrine-pancreatic-cancer\" class=\"medical medical_review\">Endoscopic ultrasound in the staging of exocrine pancreatic cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=endoscopic-ultrasound-normal-pancreaticobiliary-anatomy\" class=\"medical medical_review\">Endoscopic ultrasound: Normal pancreaticobiliary anatomy</a></li></ul></div></div>","javascript":null}